Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

BACKGROUND: Lipotoxicity leading to excessive caspase‐mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan‐caspase inhibitor that decreased serum ALT and apoptotic and inflammatory markers in subjects with chronic hepatitis. AIMS: To assess whether 28 da...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Aliment Pharmacol Ther
Päätekijät: Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2018
Aiheet:
Randomised Clinical Trial
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587784/
https://ncbi.nlm.nih.gov/pubmed/30430605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15030
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia